Dr. Reddy's Laboratories announced that the United States Food and Drug Administration (USFDA) concluded a pre-approval inspection (PAI) at its FTO-9 manufacturing facility located in Visakhapatnam, Andhra Pradesh. The inspection, conducted from October 8 to October 9, 2026, resulted in the issuance of a Form 483 with three observations.
A Form 483 is issued by the USFDA when an investigator observes any conditions that, in their judgment, may constitute violations of the Food, Drug, and Cosmetic Act and related acts. While the specific nature of the three observations was not disclosed in the company's filing, Dr. Reddy's Laboratories affirmed its commitment to address them within the stipulated regulatory timeline.
Impact on Dr. Reddy's Shares
Following the disclosure, Dr. Reddy's Laboratories shares closed at Rs 1,214.10 on Wednesday, marking a 2.06% decrease from the previous close of Rs 1,239.65. Investors will be closely monitoring the stock's performance in the wake of this development.
Company's Regulatory Compliance
As a multinational pharmaceutical company, Dr. Reddy's Laboratories regularly undergoes inspections from various global regulatory bodies. The company's prompt communication regarding the USFDA's findings underscores its commitment to transparency and adherence to manufacturing quality standards.